20 stories about Pharma
default image

Pharma Company Opko Health Retracts Decision to Delist From the Tel Aviv Stock Exchange

29.04.18|Racheli Bindman
Dually listed on Nasdaq and TASE, Opko first submitted a request to delist from the TASE in early April
מעבדה לגידול קנביס רפואי מריחואנה

Israeli Cannabis Device Developer Kanabo to Set Up Marijuana Farm in Europe

27.04.18|Tofi Stoler
To carry out the plan, Kanabo is partnering with San Francisco-Based Cannabis Extract Manufacturer Constance Therapeutics
עלה קנאביס

Israeli Pharmacies To Begin Selling Medical Marijuana Products

09.04.18|Sefi Krupsky
On April 20, selected Israeli pharmacies will begin selling prescription cannabis products as part of a pilot program for the regulation of medical marijuana sales in Israel
הפגנה מפגינים פיטורים טבע אשדוד

Teva Executive Calls Company’s Fourth Quarter “Fairly Good”

11.02.18|Dror Reich
Following the publication of the company's reports, S&P Global downgraded Teva’s corporate credit rating to junk bonds
default image

Censa Pharmaceuticals Signs Joint Development Agreement with Biotech Company Retrophin

07.01.18|Lilach Baumer
Censa, a company developing treatments for orphan metabolic diseases, is a portfolio company of Israel-based Arkin Bio Ventures
מריוס נכט 1

Check Point Founder Invests in Clinical Stage Company Regenera Pharma

02.01.18|Dror Reich
The company intends to use the funding for a phase 3 clinical trial of its drug for sudden vision loss
מיקי שפירא וינשטוק זקלר ושות' Micki Shapira a partner at Weinstock Zecler _alt Co

The Year’s Seven Key Trends in Israeli Mergers and Acquisitions

29.12.17|Micki Shapira
Even without counting the Mobileye deal, 2017 was another strong year for M&A in Israel
אורי טל טנא פרשן שוק ההון

Teva Wants to Be Like Mylan: Agile, Lean and Profitable

17.12.17|Uri Tal-Tenne
The cost-cutting plan revealed Thursday by Teva CEO Kåre Schultz showcases an intention to transform Teva into a lean and efficient generic drug company, much like main competitor Mylan
עובדי טבע בקריית שמונה מפגינים

Employees Protest Outside Teva’s Israeli Facilities

14.12.17|Omer Kabir, Yoav Stoler and Keren-Or Grinberg
The demonstrations outside the company's facilities held Thursday foreshadow a full-out strike planned by the company’s employees for Sunday
מנכ"ל טבע החדש קור שולץ 2

Teva to Let Go 14,000 Employees Over the Next Two Years

14.12.17|Lilach Baumer
The company released a statement detailing its reconstruction plan Thursday. CEO Kåre Schultz elaborated on the plan during a call with investors
default image

Israeli Pharma Company Wavelength Appoints New CEO

Pharma veteran Iftach Seri was named as Wavelength’s CEO. Formerly a Perrigo subsidiary, the company was recently sold to New York-based investment firm SK Capital for $110 million
מנכ"ל טבע החדש קור שולץ 2

Teva Announces Restructuring, Ousts Second in Command

27.11.17|Golan Hazani
The troubled Israeli drugmaker has combined its generic and specialty drug divisions, effective immediately
default image

Generic Focus made Kite Pharma Founder Leave Teva

13.11.17|Dror Reich
Founder of cancer treatment company sold to Gilead Sciences for $12 billion, says Gilead wants “to crack the cancer market"
קור שולץ מנכ"ל טבע החדש

With New CEO in Seat, Teva Lowers Outlook

02.11.17|Lilach Baumer and Dror Reich
Outlook reflects an earlier than expected launch of a generic competitor to Teva’s multiple sclerosis drug Copaxone
default image

Former Teva Executive One Step Closer to Bringing Copaxone Rival to Market

31.10.17|Lilach Baumer
Mapi Pharma announced a successful phase II clinical trial for its Copaxone equivalent GA Depot
default image

Teva Loses Copaxone Market Exclusivity

04.10.17|Lilach Baumer
Rival Mylan received FDA approval for its generic versions of Copaxone, Teva’s flagship drug
מנכ"ל טבע החדש קור שולץ 2

New CEO to Break Teva’s Copaxone Habit

11.09.17|Sophie Shulman, Dror Reich
Troubled drugmaker says new CEO must work to quickly regain its financial credibility
קור שולץ מנכ"ל טבע החדש

Teva Appoints Lundbeck's Schultz as CEO

11.09.17|Dror Reich and Micky Grunfeld
The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated
default image

Acne Cream Developer Sol-Gel files for $86 Million Nasdaq IPO

31.08.17|Dror Reich
The clinical-stage drug developer will remain a "controlled company" under current shareholder Arkin Dermatology
default image

Anti-Acne Drug Developer Plans Nasdaq IPO

15.08.17|Golan Hazani
Sol-Gel approached potential underwriters. It aims to go public before the end of the year